Related Experiment Video
Updated: Jul 15, 2026
10:39
3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
Published on: June 2, 2014
Botulinum toxin type A in chronic migraine.
1The Chicago Medical School at Rosalind Franklin University of Medicine and Science, Department of Family Medicine, North Chicago, IL, USA. dhcdoc@aol.com
Expert Review of Neurotherapeutics
|May 12, 2007
Summary
Botulinum toxin type A shows promise for chronic daily headache with migraine. Recent trials indicate positive findings, paving the way for further Phase III evaluation and improved treatment outcomes.
Area of Science:
- Neurology
- Pharmacology
Background:
- Botulinum toxin type A is under investigation by the US FDA for headache treatment.
- Previous studies on migraine and tension-type headaches yielded mixed results due to various factors.
Purpose of the Study:
- To evaluate the efficacy of botulinum toxin type A in treating chronic daily headache with a migraine component.
- To explore the mechanism of action of botulinum toxin type A in pain relief.
Main Methods:
- Conducted extensive research including individual study sites and multicenter trials.
- Focused on two large trials in patients with chronic daily headache and a migraine component.
- Performed additional analyses on this complex patient population.
Main Results:
- Two large trials demonstrated positive findings for botulinum toxin type A in the target population.
- A priori additional analyses further supported the efficacy in this complex group.
- Ongoing research aims to elucidate the mechanism of action.
Conclusions:
- Botulinum toxin type A shows potential for treating chronic daily headache with a migraine component.
- Positive trial results support further Phase III evaluation.
- Understanding the mechanism of action, particularly central sensitization, is crucial for optimizing outcomes.
Related Concept Videos
01:22Botulism
Botulism is a life-threatening neuroparalytic condition caused by botulinum neurotoxin, which is produced by the bacterium Clostridium botulinum, a Gram-positive, spore-forming, obligate anaerobe.In adults, the toxin enters the body in different ways: in foodborne botulism, the preformed toxin is absorbed in the intestine. In wound botulism, spores grow in injured tissue and release the toxin into the blood. Infant botulism differs mechanistically from adult forms. In infants, botulism commonly...
01:26Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
01:31Skeletal Muscle Relaxants: Therapeutic Uses
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx as...
01:27Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Although all competitive neuromuscular blockers are designed...
01:17Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
01:29Tetanus
Tetanus is a life-threatening neurological disorder characterized by persistent muscle contractions and spastic paralysis. It is caused by Clostridium tetani, a motile, Gram-positive, rod-shaped, obligate anaerobe. These bacteria produce terminal endospores, giving them a distinctive “lollipop” or “tennis-racket” appearance. They thrive in anaerobic environments, such as those found in deep puncture wounds.Once introduced into the body, the spores germinate into vegetative cells. These cells...